Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity ofBT7480 in Patients With Nectin-4 Associated Advanced Malignancies
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / email@example.com
The purpose of this study is to evaluate whether the investigational drug, BT7480, will be a safe and effective anticancer therapy. This is the first time BT7480 will be given to humans. BT7480 is designed to recognize and attach itself to both the Nectin-4 protein found on the surface of some cancer cells and CD137, a protein found on the surface of some immune cells. BT7480 binds to both Nectin-4 and CD137 and may activate immune cells to fight the Nectin-4-expressing cancers. Cancers include bladder cancer, breast cancer, esophageal cancer, ovarian cancer, head and neck/oral cancers, lung cancer, and stomach cancer.
Richard Carvajal, MD
|Are you at least 18 years old?
|Have you been diagnosed with advanced cancer?